Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent, or Metastatic Cervical Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.
- 21 Jun 2018 Planned End Date changed from 1 Jun 2025 to 1 Oct 2025.
- 21 Jun 2018 Planned primary completion date changed from 1 Jun 2022 to 1 Oct 2022.